<table id="id_a7df07ad-6aee-4a47-9bc4-943cf567b1e5" width="949.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_2f13464f-4393-477a-8f3c-178167d24703">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="32.9%"></col>
<col width="28.7%"></col>
<col width="38.5%"></col>
<tbody>
<tr id="id_d820269e-807e-401a-90ef-401ee4d5d681">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="bottom">Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Clinical Comment</td>
</tr>
<tr id="id_b475c7b1-f7c8-4445-8143-e15ac05cdde1">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and <br/>150 mcg levonorgestrel</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Decreased lamotrigine levels approximately 50%.</td>
</tr>
<tr id="id_2b1afaa8-ce5e-48f2-aed5-42ced53ceb31">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_fd2dd3da-3b06-4799-91fe-f4da0c63b02d">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_012c0364-ddcc-4a4b-be8c-47c80fcab38d">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels.</td>
</tr>
<tr id="id_c177f01a-f9d0-417f-9269-7e5163d63257">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_d0c3a163-6824-405e-983f-2d1bc95cb83f">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_420b3d62-f08d-466d-ab35-ffdc15877ab6">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr id="id_4d674307-100a-4cd9-b780-6242b23d3f17">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Valproate</td>
<td align="left" stylecode="Rrule" valign="top">↑ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2-fold. <br/>
</td>
</tr>
<tr id="id_02246327-ec69-473f-93db-b57110aa0ee1">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? valproate</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.</td>
</tr>
<tr id="id_b79fcc23-8d91-41ae-80a0-4e19f8259f1e">
<td align="left" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>↓= Decreased (induces lamotrigine glucuronidation). </paragraph>
<paragraph>↑= Increased (inhibits lamotrigine glucuronidation). </paragraph>?= Conflicting data. </td>
</tr>
</tbody>
</table>